The developer of a rival weight-loss treatment to those offered by Novo Nordisk and Eli Lilly said its drug had achieved positive results in liver disease trials, showing how a new class of obesity drugs can offer wider health benefits.
将与诺和诺德(Novo Nordisk)和礼来(Eli Lilly)提供的减肥药展开竞争的一种减肥药的开发商表示，其药物在肝病试验中取得积极结果，表明新型肥胖症药物能够提供更广泛的健康益处。
您已阅读7%（331字），剩余93%（4424字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。